PubMed HealthSearch

SEARCH · PubMed Health

Results for “Iodoquinol”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources

Susceptibility of an emetine-resistant mutant of Entamoeba histolytica to multiple drugs and to channel blockers.

Previously a cloned emetine-resistant mutant of the protozoal parasite Entamoeba histolytica was shown to overexpress a gene for an ameba homolog of the mammalian P-glycoprotein, a plasma membrane pump that removes hydrophobic drugs from multidrug-resistant tumor cells. Three sets of experiments were performed to better characterize the multidrug-resistant phenotype of the emetine-resistant amebae. First, the emetine resistance of the mutant amebae was reversed by concentrations of calcium and sodium channel blockers effective in reversing drug resistance by multidrug-resistant tumor cells, but it was reversed only in the presence of very high concentrations of the tricyclic antidepressants. Second, the mutant amebae showed cross-resistance to antiamebic drugs used to treat luminal infection (iodoquinol and diloxanide) but were not cross-resistant to drugs used to treat invasive disease (chloroquine and metronidazole). Third, when amebae were loaded with radiolabeled emetine, the mutant parasites released the drug at approximately 1.6 times the rate of the wild-type organisms. We conclude that the emetine-resistant E. histolytica parasites have some but not all the features of the multidrug-resistant phenotype.

Animals

Zinc therapy of acrodermatitis enteropathica.

The therapeutic effect of orally administered zinc was evaluated in an adult woman with acrodermatitis enteropathica. When she was off therapy and in clinical relapse the plasma zinc concentration (10 mug per 100 ml), serum alkaline phosphatase (3 1U per liter) and urine zinc excretion rate (39 mug per 24 hours) were extremely low. Di-iodohydroxyquin therapy was accompanied by a modest increase in plasma zinc concentrations. Oral zinc sulfate (220 mg three times a day or 50 mg twice a day) resulted in rapid and complete clinical remission, and in a return of plasma zinc, serum alkaline phosphatase and urinary zinc excretion to normal. These data are compatible with a severe zinc deficiency state and indicate that the inherited defect in this disease is either in or closely related to zinc metabolism. The beneficial effects of zinc therapy in this patient provide further confirmation of the efficacy of oral zinc in the treatment of acrodermatitis enteropathica.

Acrodermatitis

Case report. Failure of metronidazole in amebic liver abscess.

A 51-year-old man was treated with open surgical drainage and metronidazole for an amebic liver abscess. During therapy and while the original abscess was resolving, a second, noncontiguous amebic liver abscess developed. This second abscess eventually responded to emetine, chloroquine, and diodohydroxyquin therapy without surgical drainage. This unique case serves to document that new abscess may develop in the course of metronidazole therapy and illustrates the value of serial hepatoscanning in such patients.

Chloroquine

Zinc and di-iodohydroxyquinoline therapy in acrodermatitis enteropathica.

A 25-year-old patient with acrodermatitis enteropathica who had been treated with di-iodohydroxyquinoline for 20 years was changed to zinc sulphate therapy and studied under full metabolic balance control for zinc, calcium, magnesium, and inorganic phosphorus. The results obtained indicate that there is only a small overall deficit of body zinc stores in this disease and that the function of di-iodohydroxyquinoline is to increase the amount of zinc absorbed and retained by the body.

Acrodermatitis

Treatment of pulmonary aspergillosis with di-iodohydroxyquinoline.

Thirteen patients with a clinical diagnosis of pulmonary aspergillosis were treated with the anti-amoebic drug di-iodohydroxyquinoline, 1500-1800 mg/day orally, for 20 days. All were precipitin positive before treatment and all but one became negative after treatment. Sputum became negative in all of the 10 patients in whom it had been positive before treatment. Clinical improvement was marked in four patients, moderate in three, and slight in three, no change occurring in the remaining three. These results suggest that di-iodohydroxyquinoline may be of value in the treatment of pulmonary aspergillosis.

Adult